Active Ingredient(s): Avalglucosidase Alfa-ngpt
FDA Approved: * August 6, 2021
Pharm Company: * GENZYME CORP
Category: Genetic Disorders

Avalglucosidase alfa, sold under the brand name Nexviazyme, is an enzyme replacement therapy medication used for the treatment of glycogen storage disease type II (Pompe disease).[2][3] The most common side effects include headache, fatigue, diarrhea, nausea, joint pain (arthralgia), dizziness, muscle pain (myalgia), itching (pruritus), vomiting, difficulty breathing (dyspnea), skin redness (erythema), feeling of "pins and needles" (paresthesia) and skin welts ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.